Cellectis SA Net Assets
Cellectis SA net assets. Based on the latest financial reports, Cellectis SA (CLLS) has net assets worth $41.07 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($267.37 Million) and total liabilities ($226.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Cellectis SA net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $41.07 Million |
| % of Total Assets | 15.36% |
| Annual Growth Rate | 3.13% |
| 5-Year Change | -67.9% |
| 10-Year Change | -72.3% |
| Growth Volatility | 237.95 |
Net Assets of Cellectis SA (2007–2025)
Net assets of Cellectis SA from 2007 to 2025. This chart illustrates how Cellectis SA's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Cellectis SA to measure how much of total assets are equity-financed.
Annual Net Assets for Cellectis SA (2007–2025)
The table below shows the annual net assets of Cellectis SA from 2007 to 2025. For live market cap and overall valuation, see Cellectis SA stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $75.90 Million | -42.07% |
| 2024-12-31 | $131.03 Million | +54.71% |
| 2023-12-31 | $84.69 Million | -32.75% |
| 2022-12-31 | $125.94 Million | -46.74% |
| 2021-12-31 | $236.47 Million | -23.43% |
| 2020-12-31 | $308.85 Million | -13.12% |
| 2019-12-31 | $355.47 Million | -21.05% |
| 2018-12-31 | $450.27 Million | +57.49% |
| 2017-12-31 | $285.90 Million | +4.33% |
| 2016-12-31 | $274.05 Million | -4.92% |
| 2015-12-31 | $288.22 Million | +298.17% |
| 2014-12-31 | $72.39 Million | +988.46% |
| 2013-12-31 | $6.65 Million | -91.86% |
| 2012-12-31 | $81.69 Million | +120.64% |
| 2011-12-31 | $37.02 Million | -26.15% |
| 2010-12-31 | $50.13 Million | -31.54% |
| 2009-12-31 | $73.22 Million | +58.45% |
| 2008-12-31 | $46.21 Million | +6.13% |
| 2007-12-31 | $43.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cellectis SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33413100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cellectis SA Net Assets Breakdown (December 2025)
Cellectis SA net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.90 Million | 7.78% |
| Other Comprehensive Income | $-33.32 Million | -43.89% |
| Other Components | $437.45 Million | 576.34% |
| Total Equity | $75.90 Million | 100.00% |
Cellectis SA Competitors by Market Cap
The table below lists competitors of Cellectis SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maywood Acquisition Corp. Unit
NASDAQ:MAYAU
|
$85.11 Million |
|
Clearwise AG
DU:ABO
|
$85.15 Million |
|
Golden Bridge Electech Inc
TW:6133
|
$85.15 Million |
|
La Kaffa International Co Ltd
TWO:2732
|
$85.19 Million |
|
AMTD IDEA Group
NYSE:AMTD
|
$85.04 Million |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
$84.99 Million |
|
Dimerix Ltd
AU:DXB
|
$84.96 Million |
|
OncoQuest Pharmaceuticals Inc
KQ:078590
|
$84.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellectis SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 131,033,000 to 75,901,000, a change of -55,132,000 (-42.1%).
- Net loss of 67,593,000 reduced equity.
- New share issuances of 44,000 increased equity.
- Other comprehensive income increased equity by 6,221,000.
- Other factors increased equity by 6,196,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-67.59 Million | -89.05% |
| Share Issuances | $44.00K | +0.06% |
| Other Comprehensive Income | $6.22 Million | +8.2% |
| Other Changes | $6.20 Million | +8.16% |
| Total Change | $- | -42.07% |
Book Value vs Market Value Analysis
This analysis compares Cellectis SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.38x to 1.55x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $3.08 | $1.17 | x |
| 2008-12-31 | $3.27 | $1.17 | x |
| 2009-12-31 | $5.18 | $1.17 | x |
| 2010-12-31 | $3.55 | $1.17 | x |
| 2011-12-31 | $2.62 | $1.17 | x |
| 2012-12-31 | $3.96 | $1.17 | x |
| 2013-12-31 | $0.34 | $1.17 | x |
| 2014-12-31 | $2.82 | $1.17 | x |
| 2015-12-31 | $8.35 | $1.17 | x |
| 2016-12-31 | $7.65 | $1.17 | x |
| 2017-12-31 | $7.48 | $1.17 | x |
| 2018-12-31 | $10.04 | $1.17 | x |
| 2019-12-31 | $7.42 | $1.17 | x |
| 2020-12-31 | $6.68 | $1.17 | x |
| 2021-12-31 | $5.21 | $1.17 | x |
| 2022-12-31 | $2.59 | $1.17 | x |
| 2023-12-31 | $1.49 | $1.17 | x |
| 2024-12-31 | $1.45 | $1.17 | x |
| 2025-12-31 | $0.76 | $1.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellectis SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -92.66%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 4.28x
- Recent ROE (-89.05%) is above the historical average (-98.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -10.01% | -106.22% | 0.08x | 1.24x | $-8.71 Million |
| 2008 | 0.40% | 1.25% | 0.24x | 1.32x | $-4.44 Million |
| 2009 | -7.54% | -31.87% | 0.19x | 1.25x | $-12.84 Million |
| 2010 | -21.39% | -51.11% | 0.30x | 1.38x | $-15.74 Million |
| 2011 | -83.45% | -149.05% | 0.16x | 3.56x | $-34.60 Million |
| 2012 | -37.32% | -105.89% | 0.24x | 1.46x | $-37.34 Million |
| 2013 | -1212.90% | -369.38% | 0.52x | 6.35x | $-84.97 Million |
| 2014 | 0.03% | 0.09% | 0.16x | 2.26x | $-7.37 Million |
| 2015 | -7.79% | -40.81% | 0.15x | 1.29x | $-51.28 Million |
| 2016 | -23.32% | -150.10% | 0.13x | 1.21x | $-91.32 Million |
| 2017 | -37.25% | -394.51% | 0.08x | 1.25x | $-126.05 Million |
| 2018 | -19.23% | -618.12% | 0.03x | 1.22x | $-119.62 Million |
| 2019 | -28.78% | -597.01% | 0.03x | 1.48x | $-122.20 Million |
| 2020 | -25.57% | -98.14% | 0.16x | 1.65x | $-100.95 Million |
| 2021 | -38.99% | -116.68% | 0.19x | 1.73x | $-108.41 Million |
| 2022 | -83.66% | -514.78% | 0.07x | 2.21x | $-110.48 Million |
| 2023 | -119.32% | -13385.30% | 0.00x | 3.95x | $-109.53 Million |
| 2024 | -28.05% | -88.57% | 0.11x | 2.93x | $-49.86 Million |
| 2025 | -89.05% | -92.66% | 0.22x | 4.28x | $-75.18 Million |
Industry Comparison
This section compares Cellectis SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellectis SA (CLLS) | $41.07 Million | -10.01% | 5.51x | $85.08 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more